



April 6, 2020

Dear Duchenne Patient Community,

We are currently experiencing an unprecedented situation in which the COVID-19 outbreak is affecting families, businesses, communities, and our way of life. We are all facing new challenges and dynamic circumstances, but we remain committed to caring deeply for the patients we serve and our employees.

For our program in Duchenne muscular dystrophy, we continue to do everything we can to progress our pre-clinical work during this time.

Audentes will continue to monitor the situation very closely as it evolves and will provide updates as soon as we are able. We are working in accordance with guidance issued by global regulatory bodies and evaluating all options that will allow us to continue to advance our programs as soon as it is safely possible. Please do not hesitate to contact [**patientadvocacy@audentestx.com**](mailto:patientadvocacy@audentestx.com) directly if you have any questions.

We remain committed to advancing our mission to develop genetic medicines for patients around the world.

Sincerely,

The Audentes Patient Advocacy & Engagement Team
patientadvocacy@audentestx.com